NSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹472.70
- Market cap
- ₹18,085 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 170.2×Sector 46.5×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Board Meeting Date
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.
Cohance Lifesciences Other Announcement
Cohance Lifesciences Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b), disclosing promoter and public shareholding data as of September 30, 2026.
Cohance Lifesciences Regulatory Approval
Cohance Lifesciences received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
Cohance Lifesciences Employee Stock Options
Cohance Lifesciences Ltd. approved the grant of 2,60,194 stock options under ESOP 2026 and 6,14,594 stock options under ESOP 2023 to eligible employees.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Mr. Abhimanyu Ojha as the new Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026.
Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.